Hong Kong Stock Movement
Stocks with High Trading Volume in the Industry
Shanghai Pharmaceuticals rose 0.49%. According to recent important news:
<ol>
<li>
On September 15, Shanghai Pharmaceuticals' controlling shareholder, Shanghai Pharmaceuticals Holding, increased its stake in the company, raising its holding ratio to 8.104%. This move demonstrates confidence in the company's future development, driving the stock price up. Data source: Announcement.
</li>
<li>
On September 15, CITIC Securities raised the target price for Shanghai Pharmaceuticals' H shares to HKD 14.2, maintaining an &#34;Outperform&#34; rating, reflecting the market's structurally optimistic attitude towards the company. Data source: Report.
</li>
<li>
On September 17, Shanghai Pharmaceuticals' R&amp;D investment in the first half of the year reached CNY 1.148 billion, showing the company's continued investment in innovative drugs, enhancing market confidence. Data source: Financial report. The pharmaceutical industry shows structural optimism, with significant capital inflow.
</li>
</ol>
China National Pharmaceutical Group rose 0.11%. Based on recent important news:
<ol>
<li>
On September 15, CITIC Securities released a report stating that although China National Pharmaceutical Group's performance in the first half of the year did not turn profitable, it holds a structurally optimistic attitude towards the industry, as medical insurance expenditures may be relaxed, optimizing centralized procurement policies, and the domestic interest rate reduction cycle helps improve financial leverage. The target price was raised to HKD 24.5, maintaining an &#34;Outperform&#34; rating.
</li>
<li>
On September 16, China National Pharmaceutical International plans to increase its investment in Luzhong Investment, indirectly controlling 19.5% of Shandong Pharmaceutical Glass. Asset adjustments are closely related to policies, and state-owned enterprise reforms are entering a deepening phase, with mergers and integrations expected to remain the main line until 2025.
</li>
<li>
On September 15, Citic raised the target price for China National Pharmaceutical Group from CNY 20 to CNY 24.5, maintaining an &#34;Outperform&#34; rating, believing that China National Pharmaceutical Group is the preferred choice. The pharmaceutical industry's policy optimization and interest rate reduction cycle are supportive.
</li>
</ol>
Stocks with High Market Capitalization in the Industry
Baiyunshan fell 0.16%. According to recent key news:
<ol>
<li>
On September 15, Baiyunshan Pharmaceutical's selective RET small molecule inhibitor BYS10 tablets received feedback from the National Medical Products Administration's Drug Evaluation Center, agreeing to apply for listing using a Phase II single-arm clinical trial in the future. This news put some pressure on the company's stock price, leading to a decline.
</li>
<li>
On September 16, Baiyunshan Pharmaceutical received the &#34;Drug Supplement Application Approval Notice&#34; for Abdominal Anesthesia Tablets, Kunling Pills, Shenxi Dan, Yigan Ling Tablets, and Mai'an Granules. Although there is no significant impact on the company's current performance, it helps enhance the market competitiveness of the products.
</li>
<li>
On September 15, Baiyunshan Pharmaceutical's BYS10 tablets showed strong and lasting anti-tumor activity in Phase I clinical trials, and the CDE agreed to apply for listing using a Phase II single-arm clinical trial in the future. This news had a certain impact on the company's stock price. The traditional Chinese medicine industry has performed steadily recently, with significant policy support
</li>
</ol>

00574

PASHUN INT'L fell 16.90%; Shanghai Pharmaceuticals rose 0.49%, with a transaction volume of HKD 45.47 million; China National Pharmaceutical Group rose 0.11%, with a transaction volume of HKD 44.41 million; YaoShibang fell 1.80%, with a transaction volume of HKD 36.39 million; Baiyunshan fell 0.16%, with a market value of HKD 30.2 billion

Hong Kong Stock Movement: PASHUN INT'L down 16.90%